Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 330.20 DKK | -1.73% | +4.69% | +63.95% | |
| Nov. 30 | Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers | CI |
| Nov. 15 | Nordic Shares Closed Up Wednesday; ALK-Abello Series B Led Increases | DJ |
| Sales 2023 * | 391 M 57.07 M | Sales 2024 * | 1,187 M 173 M | Capitalization | 19.26 B 2,812 M |
|---|---|---|---|---|---|
| Net income 2023 * | -494 M -72.13 M | Net income 2024 * | - 0 | EV / Sales 2023 * | 44,3x |
| Net cash position 2023 * | 1,935 M 283 M | Net cash position 2024 * | 2,800 M 409 M | EV / Sales 2024 * | 13,9x |
| P/E ratio 2023 * | -28,1x | P/E ratio 2024 * | -163x | Employees | 249 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.19% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.73% | ||
| 1 week | +4.69% | ||
| Current month | -1.73% | ||
| 1 month | +10.43% | ||
| 3 months | +27.89% | ||
| 6 months | +24.79% | ||
| Current year | +63.95% |
1 week
315.80
346.00
1 month
274.40346.00
Current year
198.00346.00
1 year
189.30346.00
3 years
69.55346.00
5 years
69.55346.00
10 years
57.50346.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 2009 | |
| Director of Finance/CFO | - | Oct. 31 | |
Danilo Verge
CTO | Chief Tech/Sci/R&D Officer | - | 2020 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 65 | 2019 |
| Chairman | 68 | 2014 | |
Kirsten Drejer
BRD | Director/Board Member | 67 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.04% | 4 M€ | -9.35% | ||
| 2.01% | 67 M€ | +6.32% | - | |
| 0.67% | 33 M€ | -5.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 330.20 | -1.73% | 315,124 |
| 23-11-30 | 336.00 | +2.63% | 395,391 |
| 23-11-29 | 327.40 | +1.99% | 158,350 |
| 23-11-28 | 321.00 | +0.25% | 354,063 |
| 23-11-27 | 320.20 | +1.52% | 146,646 |
Delayed Quote Nasdaq Copenhagen, December 01, 2023 at 10:59 am EST
More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
2023-12-05
- R&D Day
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
330.20DKK
Average target price
365.33DKK
Spread / Average Target
+10.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.95% | 2 807 M $ | |
| +21.60% | 90 488 M $ | |
| +12.94% | 86 658 M $ | |
| +2.47% | 34 551 M $ | |
| +19.81% | 26 777 M $ | |
| -33.83% | 23 629 M $ | |
| -26.62% | 20 547 M $ | |
| -14.75% | 19 529 M $ | |
| -1.94% | 11 507 M $ | |
| +20.17% | 10 906 M $ |
